Market Analysis From Decision Resources
This article was originally published in Pharmaceutical Approvals Monthly
You may also be interested in...
Berlex/Chiron’s Betaseron indication has been expanded to include secondary progressive multiple sclerosis, but approval is limited to the subset of patients who continue to have relapsing disease.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011